GlobeNewswire

ASM EXPANDS ITS EPITAXY PRODUCT OFFERINGS WITH NEW INTREPID® ESA™

Share

Almere, The Netherlands
July 7, 2021, 5.45 p.m. CET

New epitaxy tool addresses 300mm applications for power, analog and wafer markets

ASM International N.V. (Euronext Amsterdam: ASM) today introduced its Intrepid® ESA epitaxy tool for 300mm applications for power and analog devices, and for epitaxial silicon wafers. Based on the proven, high-volume-manufacturing Intrepid platform, the new ESA tool expands ASMs atmospheric epi offerings with ASMs first 300mm atmospheric cluster tool. The Intrepid ESA offers best-in-class on-wafer performance.

An expanding range of semiconductors are needed for 5G smartphones, internet of things (IoT), edge computing, automotive, sensors, renewable energy, and much more. ASM’s epitaxy tools are critical for depositing silicon-based films in diverse, fast growing applications for analog and power devices, as well as for silicon wafer manufacturing.

For chipmakers, the metrics that drive product yield and fab operational cost will be of utmost importance: the ability to manufacture a wide range of different products; on-wafer performance metrics, such as within-wafer and wafer-to-wafer uniformity; and productivity and foot print efficiency.

ASM has responded to this critical customer need with the introduction of the Intrepid ESA. The Intrepid ESA has innovative technologies and features that provide unmatched in-film performance and reactor availability. These include a hot quartz isothermal reactor for superior temperature uniformity, allowing for the deposition of films as thick as 85µm without interruption and reactor clean, a significant throughput and device performance benefit. Furthermore, ASM has introduced the first 10-port MFC-based advanced gas injection system, called AEGIS™, providing flexibility for film thickness profile control.

To further enhance device performance and die yield, ASM has pioneered real-time closed-loop wafer temperature control during epi processing allowing for the in-situ measurement and control of wafer temperature simultaneously in different areas of the wafer during processing. This first-of-its-kind feature enables the elimination of thermal gradient induced wafer slip in high temperature processing, resulting in improved die yield. In addition, Intrepid ESA can hold up to four reactors on its XP platform. It is compact in size, has dual gate valves for isolating each chamber with the XP platform, and has independent gas delivery systems.

These features enable considerably higher throughput and thus improved platform efficiency (wafer output per square meter) which we view as unique strengths of the Intrepid ESA.

“Innovative process control features such as AEGIS and closed loop chamber temperature control uniquely position Intrepid ESA as the best choice for our customers running applications for power and analog devices, and for wafer manufacturers,” said Dr. Hichem M’Saad, Executive Vice President and General Manager of ASM’s Global Products. “ASM strives to enable customers to scale cost effectively and with greater yield.”

More than 30 Intrepid ESA reactors, with repeat orders, are in production at different sites in Asia and the Unites States.

About ASM International

ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com.

Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, changes in import/export regulations, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

CONTACT

Investor and media contact:
Victor Bareño
T: +31 88 100 8500
E: victor.bareno@asm.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company27.7.2021 07:01:34 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 27, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2021. Business highlights Daridorexant for the treatment of insomnia under review with US FDA, EMA, and SwissmedicNine scientific presentations for daridorexant shared at SLEEP 2021Ponesimod to treat relapsing forms of multiple sclerosis was approved by the US FDA and the European Commission, Idorsia receives first income from the revenue-sharing agreement in respect to ponesimodClazosentan NDA for the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) submitted to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in March 2021“SOS-AMI” Phase 3 registration study with selatogrel in suspected acute myocardial infarction (AMI) initiated in June 2021Phase 2 study with ACT-539313 for binge eating disorder initiated in March 2021Results for MODIFY Phase 3 study with lucerastat for Fabry

Hyloris to Report 2021 Half-Year Results on 4 August 202127.7.2021 07:00:00 CEST | Press release

Liège, Belgium – 27 July 2021 –Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial results and to provide a business update. The presentation will be followed by a live Q&A session. The webcast may be accessed on the Events page of the company’s website or by clicking here. To participate in the Q&A session of the conference call, please dial one of the following numbers, ten minutes prior to the start of the live webcast: Belgium +32 2 79 338 47 France +33 1 70 700 781 Netherlands + 31 20 795 6614 United Kingdom +44 2071 928 338 United States +1 646 741 3167 Confirmation code 2687826 Following the call, a replay of the webcast will be available on the events page of the Hyloris website. About Hyloris Phar

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor27.7.2021 07:00:00 CEST | Press release

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation)i; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Jersey City, N.J., Geneva, Switzerland, July 27, 2021 - Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatme

Wereldhave N.V.: Results H1 202127.7.2021 07:00:00 CEST | Press release

Key items Major step in phasing out France: sold four out of six French assets for € 305mBenelux disposal program finalized, Koningshoek sold above book value LTV down to 46% - pro-forma for four asset French disposal 42%Dutch valuations stabilizing for the first time in nine valuation roundsAs a result of disposals, outlook 2021 direct result now at € 1.75 - 1.85 per shareOutlook direct result 2022 reiterated at € 1.40 - € 1.50 per share; to be followed by 4 - 6% annual growthDividend guidance 2021 minimum € 1.00 per share Attachment Wereldhave pr 2021-H1 - vFINAL

Leasinvest Real Estate SA: Publication of a transparency notification26.7.2021 18:00:00 CEST | Press release

PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 26 July 2021 issued by AG Insurance, shows that both a passive threshold overrun and a drop below the minimum threshold took place, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AG Insurance in Leasinvest Real Estate has therefore decreased to 2.58% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun - Drop below the minimum threshold NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress Ageas SA/NV Rue du Marquis 1, 1000

PRESS RELEASE: BIGBEN: Q1 2021/22 Sales26.7.2021 17:50:00 CEST | Press release

Bigben Press release Lesquin, 26 July 2021 18:00 hrs Q1 2021/22 Sales: 56.7 M€ (+2.8%) High sales historyforNacon Gaming Favourable base effect for Audio-Telco Confirmation of FY 2021/22 and FY 2022/23 targets IFRS – M€ Sales 2021/2022 2020/2021 Change 1st Quarter Nacon Gaming Bigben Audio-Telco 56.7 33.7 23.0 55.2 38.0 17.2 +2.8% -11.3% +33.9% Non audited data In Q1 FY 2021/22 (April 1 to June 30, 2021), Bigben posted sales of €56.7 million, an increase of 2.8%, driven by Audio-Telco, which benefited from a favourable comparison basis, unlike the Nacon Gaming business unit, demonstrating the benefit from being present across several markets. NACON GAMING In Q1 2021/22, Nacon achieved sales of 33.7 M€, down 11.3% on Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. Games: The segment posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, whose back catalogue sales had been boosted by 340% by lockdown. The back catalogue demons

PRESS RELEASE: NACON: Q1 2021/22 Sales26.7.2021 17:45:00 CEST | Press release

Press release Lesquin, 26 July 2021 18 :00hrs Q1 2021/22 Sales : 33.7 M€(-11.3%) High comparison basisBack catalogue résilience Confirmation ofFY 2021/22 and FY 2022/23targets IFRS – M€ Sales Non audited data 2021/2022 2020/2021 Change 1st Quarter Games Accessories Others(1) 33.7 12.2 20.6 0.9 38.0 14.5 22.5 0.9 - 11.3% -16.0% -8.8% + 0.5% (1)Mobile and Audio sales. In Q1 2021/22 (from 1 April to 30 June 2021), Nacon achieved sales of 33.7 M€, down 11.3% compared to Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. GAMES The video games business posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, when back catalogue sales were boosted 340% by lockdown. However the good performance of the back catalogue demonstrated its resilience with sales of 9.2 M€ against 10.8 M€ in Q1 2020/21 during the first lockdown, to be compared with 2.4 M€ in Q1 2019/20. The Roguebook (81% positive reviews on Steam) and Pro Cycling Management / To